Results 91 to 100 of about 10,586,291 (388)

The X-ray luminosity function of active galactic nuclei in the redshift interval z=3-5 [PDF]

open access: yes, 2015
We combine deep X-ray survey data from the Chandra observatory and the wide-area/shallow XMM-XXL field to estimate the AGN X-ray luminosity function in the redshift range z=3-5.
A. Georgakakis   +16 more
semanticscholar   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

open access: yesMolecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop   +10 more
wiley   +1 more source

The Luminosity Function of Galaxies as modeled by a left truncated beta distribution

open access: yes, 2014
A first new luminosity functions of galaxies can be built starting from a left truncated beta probability density function, which is characterized by four parameters.
Zaninetti, L.
core   +1 more source

MAMMOTH-Subaru. V. Effects of Cosmic Variance on Lyα Luminosity Functions at z = 2.2–2.3

open access: yesThe Astrophysical Journal
Cosmic variance introduces significant uncertainties into galaxy number density properties when surveying the high-redshift Universe with a small volume.
Ke Ma   +10 more
doaj   +1 more source

DETAILED SHAPE AND EVOLUTIONARY BEHAVIOR OF THE X-RAY LUMINOSITY FUNCTION OF ACTIVE GALACTIC NUCLEI [PDF]

open access: yes, 2015
We construct the rest-frame 2–10 keV intrinsic X-ray luminosity function (XLF) of active galactic nuclei (AGNs) from a combination of X-ray surveys from the all-sky Swift BAT survey to the Chandra Deep Field South.
T. Miyaji   +21 more
semanticscholar   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

open access: yesMolecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva   +5 more
wiley   +1 more source

The luminosities of the brightest cluster galaxies and brightest satellites in SDSS groups

open access: yes, 2012
We show that the distribution of luminosities of Brightest Cluster Galaxies in an SDSS-based group catalog suggests that BCG luminosities are just the statistical extremes of the group galaxy luminosity function.
Aseem Paranjape   +25 more
core   +1 more source

The mid-IR Luminosity Function at z<0.3 from 5MUSES: Understanding the Star-formation/AGN Balance from a Spectroscopic View [PDF]

open access: yes, 2011
We present rest-frame 15 and 24 um luminosity functions and the corresponding star-forming luminosity functions at ...
Armus   +44 more
core   +3 more sources

The galaxy luminosity function in groups and clusters: the faint-end upturn and the connection to the field luminosity function [PDF]

open access: yes, 2015
We characterize the luminosity functions of galaxies residing in $z\sim0$ groups and clusters over the broadest ranges of luminosity and mass reachable by the Sloan Digital Sky Survey.
Ting-Wen Lan, B. M'enard, H. Mo
semanticscholar   +1 more source

RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR‐targeted therapies

open access: yesMolecular Oncology, EarlyView.
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy